What are Darzalex side effects?
In clinical studies, the most common side effects seen with Darzalex™ (daratumumab, Janssen/Genmab) included:
- Infusion reactions
- Back pain
- Upper respiratory infection
The most common serious side effects included low lymphocyte, red blood cell, neutrophil, and platelet counts.
In clinical trials, severe infusion reactions, such as spasms of the muscles in the major airways of the lung, low oxygen levels, difficulty breathing, and high blood pressure, have been seen with Darzalex. For this reason, patients receive premedication with antihistamines, fever-reducing agents, and steroids before infusion of Darzalex to reduce the risk of infusion reactions. Following the infusion of Darzalex, patients also receive a steroid to reduce the risk of delayed infusion reactions.
How are side effects of Darzalex managed?
Patients who experience an infusion reaction will have their Darzalex infusion stopped and their symptoms treated. After symptoms resolve, the infusion may be resumed at a slower rate. Darzalex will be discontinued in patients who experience a life-threatening infusion reaction or multiple severe reactions.
Can Darzalex affect laboratory testing?
Because Darzalex binds to the CD38 marker on red blood cells, it may interfere with testing performed for blood transfusions. As a result, patients should be typed and screened prior to beginning treatment with Darzalex.
As Darzalex is an IgG monoclonal antibody, it can be detected on tests used for the clinical monitoring of M protein and may impact the determination of complete response and of disease progression in some patients with IgG myeloma